Advertisement
UK markets close in 3 hours 36 minutes
  • FTSE 100

    8,048.72
    +24.85 (+0.31%)
     
  • FTSE 250

    19,713.14
    +113.75 (+0.58%)
     
  • AIM

    753.45
    +4.27 (+0.57%)
     
  • GBP/EUR

    1.1605
    +0.0016 (+0.14%)
     
  • GBP/USD

    1.2385
    +0.0034 (+0.28%)
     
  • Bitcoin GBP

    53,292.89
    +97.86 (+0.18%)
     
  • CMC Crypto 200

    1,419.92
    +5.16 (+0.36%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    81.33
    -0.57 (-0.70%)
     
  • GOLD FUTURES

    2,315.60
    -30.80 (-1.31%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    18,041.81
    +181.01 (+1.01%)
     
  • CAC 40

    8,085.99
    +45.63 (+0.57%)
     

Wall Street Sees Upside of More than 17% for JNJ in the Next Year

Wall Street Sees Upside of More than 17% for JNJ in the Next Year

Over the last few quarters, Johnson & Johnson (JNJ) has seen a number of factors affecting investor sentiments surrounding its stock. The company, however, posted strong results for the first quarter on April 17, exceeding analysts’ estimates. In this article, we’ll take a look at analysts’ recommendations on JNJ for the next 12 months.